Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 35Glioblastoma 24Carcinoma, Non-Small-Cell Lung 21Ovarian Neoplasms 14Carcinoma, Hepatocellular 14Brain Neoplasms 14Carcinoma, Renal Cell 13Pancreatic Neoplasms 12Neoplasms 10Neoplasm Metastasis 10Glioma 10Breast Neoplasms 10Colonic Neoplasms 8Astrocytoma 8Melanoma 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Liver Neoplasms 6Gliosarcoma 6Endometrial Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Cancer Metastatic 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Oligodendroglioma 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

olaparib 1oblimersen 1lutetium Lu 177 dotatate 1Fluorodeoxyglucose F18 1FPP(RGD)2 1Erlotinib Hydrochloride 1Epirubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esthesioneuroblastoma, Olfactory × Bevacizumab × Clear all
NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
66 enrolled
CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡